All In MedTech

FDA Clearance Tracker · P970038

TANDEM-R FREE PSA IMMUNORADIOMETRIC ASSAY/TANDEM-MP FREE PSA IMMUNOENZYMETRIC ASSAY

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 10, 1998 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Mar 10, 1998

Approved

Time to decision

193 days

Received Aug 29, 1997. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P970038
Device name
TANDEM-R FREE PSA IMMUNORADIOMETRIC ASSAY/TANDEM-MP FREE PSA IMMUNOENZYMETRIC ASSAY
Applicant location
Brea, CA
Received
Aug 29, 1997
Decided
Mar 10, 1998
Decision
Approved
Supplements
42 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MTG

FDA's approval statement

As written in FDA's record.

Approval for the Tandem(R)-R free PSA assay and Tandem(R)-MP free PSA assay. The Tandem(R)-R free PSA Immunoradiometric Assay is an In Vitro device for the quantitative measurement of free prostate specific antigen (free PSA) in human serum. The Tandem(R)-MP free PSA Immunoenzymetric Assay is an In Vitro device for the quantitative measurement of free prostate specific antigen (free PSA) in human serum. Hybritech's Tandem free PSA assays are intened to beused with Tandem (total) PSa to calculate the ration of fee PSA to total PSA expressed as a percentage (percent free PSA). Percent free PSA as measured by Hybritech's Tandem assays is indicated for use as an aid in distinguishing prostate cancer from benign prostatic condtions, when used in conjuction with Tandem (total) PSA for prostate cancer detection in men aged 50 years and older with total PSA between 4 and 10 ng/ml and digital rectal examination finding that are not suspicious for cancer. Prostatic biopsy is required for diagnosis of cancer.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MTG. The earliest in FDA's data is P950021, decided Dec 22, 1995.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Beckman Coulter, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.